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Despite a significant and continuous increase in medical
research spending, the number of new drugs approved and
new drug targets identified each year has remained almost
constant for the past 20-25 years, with about 20 new drugs
and about five new targets per year. Lengthy development
procedures and the high risk of unexpected side-effects in
advanced-stage clinical trials reduce the ability of the drug
development process to be innovative. At this rate it will
take more than 300 years to double the number of available
drugs [1]. However, there are several ways to overcome
these burdens. Promising areas of drug design include:
wide-range screens of existing drugs, seeking novel
applications; combination therapy, that is, the use of several
drugs or short DNA oligomers, called aptamers, together [2-
4]; and the development of multi-target drugs [5].
The organization of our rapidly growing knowledge on
diseases, disease-related genes, drug targets and their struc-
tures, and drugs and their chemical structures gives us another
exciting way to discover novel areas of drug development.
Several networks have recently been constructed to help drug
discovery [1,6-9]. In the network concept a complex system is
perceived as a set of interacting elements bound together by
links. Links usually have a weight, which characterizes their
strength such as the affinity of binding between the two
elements, or the propensity of one element to act on the other.
Links can also be directional, when one of the elements has a
larger influence on the other than vice versa [10,11].
In a recent study in BMC Pharmacology, Nacher and
Schwartz [8] compiled a drug-therapy network in which all
US-approved drugs and associated human therapies - that
is, the therapeutic properties of the drugs involved accor-
ding to the Anatomic Therapeutic Chemical (ATC) classifi-
cation - were connected to each other. From a bipartite
network of therapies and drugs (in which therapies were
connected to drugs, but drugs were not connected to other
drugs or therapies to other therapies) they constructed two
other networks: a drug network, in which two drugs were
connected if they were both involved in at least one
common therapy; and a therapy network, in which two
therapies were connected if a particular drug was implicated
in both therapies. Their analysis [8] provides the first view
of the relationships between therapies as defined by drug-
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overcoming the cellular robustness that can prevent drugs from working.
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connect distinct classes of therapy in a few steps.
Both the drug and the therapy networks [8] proved to be small
worlds; that is, distant therapies were separated by an average
of less than three chemicals [10,11]. Highly connected
therapies, ‘therapy hubs’, are likely to be relevant in the
therapy network, because this network behaved in a manner
close to that of a tree-like network, in which the relative
importance of hubs is high. Most drugs (79%) were
grouped in clusters connected to a specific therapy. How-
ever, a minority of drugs (21%) formed bridges spanning
different therapeutic classes; these drugs may have a par-
ticular significance.
Nacher and Schwartz [8] computed several measures of
network ‘centrality’ characterizing the importance of the
drugs in the network context of various therapies. They
identified a subnetwork of the bridging drugs with high
‘betweenness centrality’ (drugs that participated in a large
number of shortest paths connecting other drugs) in the
drug-therapy network; these include scopolamine, morphine,
tretionin and magnesium sulfate. For example, tolbutamide
and magnesium sulfate defined a key shortest path of two
steps between the distant classes of therapy ‘insulins and
analogs’ and ‘dermatological preparations’. Apparently
unrelated disorders were thus separated by a much lower
number of chemicals than might be expected. Most drugs
act on one target, but a few drugs act on a large number of
targets. Nacher and Schwartz [8] propose that drugs that
have a high betweenness centrality and act on multiple
targets may influence multiple metabolic pathways, and
they especially highlighted hydroxocobalamin, vitamin B3,
vitamin B12, atropine, ophenadrine and procaine as
members of this category.
The network approach not only gives us a systematic way to
organize our vast databases, but also provides a visual image
that can help us to understand the daunting complexity of
these systems. However, many networks, such as that of the
1,360 individual chemical substances studied by Nacher and
Schwartz [8], are too big for easy visualization. The ATC
classification system used by these authors [8] gave them the
opportunity to construct a hierarchical representation of
drug-therapy information, in which we can zoom in from
the top layer of 15 anatomical main therapeutic groups,
through the 66 therapeutic subgroups (second layer), the
123 pharmacological subgroups (third layer), the 448
chemical subgroups (fourth layer) until reaching the fifth
layer of 1,360 individual chemical substances. Where the
dataset is not as straightforwardly hierarchical as the ATC
classification [8], network hierarchy can be explored by
various other techniques [12-14].
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To show the rich context through which the results of
Nacher and Schwartz [8] can be interpreted, we show the
power of network approaches for constructing various
drug-target and related networks, for predicting new drug
targets, and to get around unwanted resistance and side
effects of drugs. These tools promise to increase the
number of novel drug targets and improve the approval
rate of new drugs.
When thinking about the possible network representations
of diseases, drugs and drug targets, the elements of the
network first have to be defined. For a list of the available
databases of drugs and related information, see Table 1. The
next step is to find a general rule determining the elements
that are linked in the particular network and the nature
(such as weight or directionality) of the links connecting
them. Besides the drug-therapy network already mentioned
[8], several other, recently published network-building rule-
sets [1,6,7,9] give additional exciting and novel information
on the vast datasets of diseases, drugs and drug targets. A
summary of these representations is shown in Figure 1.
In some of these approaches [1,6,7,9], the network can be
constructed by either linking two drug-target proteins if
both bind one or more compounds, or by linking two
compounds (drugs) if both have at least one protein as a
common target. One result from this analysis is that the
average molecular weight of compounds becomes smaller
and smaller as we go from preclinical drug candidates to
Phase I, II, III and approved drugs. Other physicochemical
properties, such as hydrophobicity and the ability to form
hydrogen bonds, reduce further the number of drug candi-
dates that can be given orally, which is the method
normally desired [7].
The analysis of the drug-target network [1,6,7,9] also reveals
further elements of the low-risk behavior of the pharma-
ceutical industry. The network is particularly enriched in
highly targeted proteins, and elements with many neighbors
(called hubs) are preferentially connected to each other,
forming a so-called ‘rich club’. This is a result of the ten-
dency to target an already validated target protein with
alternative or follow-up compounds. Experimental drugs act
on a greater diversity of target proteins, and show a more
diverse localization of the targets than the plasma
membrane, which is usually the preferred site of action. So
far, however, these efforts have not led to a significant
expansion of novel targets, that is, novel classes of protein
or cellular compartments [6].
An additional approach to deciphering meaningful infor-
mation for drug development efforts is to link human
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the development of the disease. This human disease net-
work has also been converted to the other possible network
of disease genes, in which two genes are connected if they
are associated with the same disorder [15]. Among human
diseases, several types of cancer, such as colon and breast
cancer, are hubs that are genetically connected to more than
30 distinct disorders. Disease genes that contribute to a
common disorder often have protein products that form
larger complexes, are often co-expressed and have similar
major functions [15]. Interestingly, those inheritable disease
genes that are not essential occupy a peripheral position in
the cellular network. This is in stark contrast to essential
genes, which are more central [16]. By contrast with
inheritable disease genes, disease genes associated with
somatic mutations, such as somatic cancer genes, have a
central position in cellular networks [15]. When comparing
drug-target networks with the related diseases, an ongoing
shift of drug development can be observed towards ‘novel
diseases’ with associated genes that were not previous drug
targets [6].
In the analysis and visual representation of drug-therapy
and drug-target networks, the weight of the links (such as
the number of drugs binding to both of two linked targets
in the drug-target network) is seldom assessed. In addition,
these networks have not been thoroughly analyzed by
defining their groups, or modules [10-14]. Both additions
will certainly provide more detailed information on these
exciting datasets. Important messages could be drawn from
the additional networks shown in Figure 1. Not only drugs,
but also their respective drug targets, can be linked to the
various therapies. As an additional, rich source of data,
patient records can be analyzed for the diseases diagnosed
as well as the drugs prescribed. Patient medication records
can be transcribed to a patient-drug target network, which
may reveal novel aspects of the phenotype variability of
diseases. Yet another set of data lies in the symptoms of
patients, which can serve as a basis to construct symptom-
disease, symptom-therapy or symptom-drug networks
(Figure 1).
Drugs may also form a structural network, where two drugs
are linked if they contain the same, signature-like chemical
segment or feature. Drugs can also be assembled to form a
side-effect network, or toxicity network, which may give an
overall view of these two key maladies of drug develop-
ment. As more and more data will be available in the future,
patient symptoms can be extended by appropriately selected
patient transcriptome, proteome, metabolome, oral micro-
biome and gut microbiome data. This ‘inflation’ of drug
and drug-related networks is unlikely to solve the current
problems of drug design; rather, it may be that the more
networks we add, the less clarity and focus we will enjoy.
Drug- and disease-related network representations will
certainly have their own evolution, however, and it is not
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Name Description References
DrugBank A bioinformatics-cheminformatics resource combining detailed drug data  [26]
with comprehensive drug target information with over 4,900 drug entries 
(about 3,500 experimental) and about 1,500 non-redundant protein entries
Drug-target Network Network data of 890 drugs and 394 target human proteins [6]
Drug-Therapy Network Three layers of drug-therapy networks according to the ATC classification [8]
Online Mendelian Inheritance in Man (OMIM) A knowledgebase of human genes and genetic disorders [27]
Potential Drug Target Database (PDTD) A three-dimensional drug target structure database with a target  [28]
identification option
Predicted drug targets A set of 1,383 predicted drug targets [17]
Protein ligand network A network of 4,208 ligands and about 15,000 binding sites [9]
Therapeutic Target Database Lists over 1,500 therapeutic targets, disease conditions and  [29]
corresponding drugs
FDA Orange Book Approved drug products with therapeutic equivalence evaluations [32]
Investigational Drugs database (IDdb) Thomson Investigational drugs database including information on 107,000  [33]
patents, 25,000 investigational drugs and 80,000 chemical structures
TDR Targets Database Identification and ranking targets against neglected tropical diseases [34]yet clear which of them will give the most straightforward,
non-obvious visual and analytical information.
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Existing segments of drug-target networks may have hidden
information on additional drug targets that are not yet
included in the network. Extension of existing networks by
predicting links and elements is a recent, exciting field of
network studies [13,17,18]. The identification of novel drug-
target candidates can be accomplished by finding missing
links in all networks in which drug targets serve as links, for
example, in drug [1,6,7,9], therapy [8] or patient networks
joined by common drug targets. Methods for discovering new
links can identify new nodes in all bipartite networks, in
which any of the nodes of one type can be converted to links
joining nodes to the other type. This may give us novel
methods to predict, discover, test and extend gene regulatory,
metabolic, opinion (recommendation), collaboration (co-
authorship), sexual and any other affiliation-type networks.
Robustness is an intrinsic property of cellular networks that
enables them to maintain their functions despite various
perturbations [19]. Networks of different topology vary by
orders of magnitude in their robustness to mutations and
noise. Enhanced robustness is a property of only a very
small number of all possible network topologies [20].
Cellular networks in both health and disease belong to this
extreme minority and show this robust behavior.
Many times when a drug fails or produces side effects,
cellular robustness provides most of the explanation. A drug
can be ineffective when the robustness of cellular networks
of disease-affected cells or parasites compensates for the
changes caused by it. By contrast, drug side effects can be
the result of hitting an unexpected point of fragility in the
affected networks [21]. Robustness analysis is already being
used to reveal primary drug targets [22], and the first
methods have also been established to give a quantitative
measure of changes in robustness during drug action [23].
Cellular robustness can be caused by strong links forming
negative or positive feedbacks that help the cell to return to
the original state or jump to another, respectively; by weak
links that provide alternative, redundant pathways; or by a
range of other mechanisms [11,19,21]. But achieving
robustness always has a price. Robust cells have their fragile
point, their ‘Achilles heel’, and cannot be optimized for all
other aspects of cellular life, such as proliferation. This gives
us chances to conquer or redirect cellular robustness by the
application of drugs. We can develop drugs that, for
example, find the Achilles heel of the cellular robustness of
disease-affected cells or parasites, or that decrease robust-
ness, for example, by inhibiting the effect of weak links
[11,19,21]. Note that a decrease in robustness makes the
cellular network noisier and less predictable, which means
that robustness-decreasing drugs will be more difficult to
find than conventional drugs using currently available
analytical methods that assume an ‘equilibrium’ network.
The development of ‘fuzzy’, stochastic network analysis
[14,18] and the comparison of network time series may
help to overcome this difficulty.
Our current knowledge on cellular networks and their
analytical methods has arrived at a time when testing the
effects of drug candidates with known cellular targets or
target-sets on the robustness of cellular networks is becoming
possible. A robustness test, revealing both resistance-related
failures and side effects, should, in our opinion, be a
mandatory element of standard drug-development protocols.
The more we know about tissue- and disease-specific changes
in cellular networks and about variations in these changes
between individuals, the better we will be able to predict the
efficiency of drugs in in silico experiments.
In summary, the recently published drug-therapy [8] and
drug-target networks [1,6,7,9] as well as their potential
extensions (Figure 1) provide a powerful and exciting tool
for the organization of the expanding drug-development
data and give us a global view on major trends and
limitations. The advent of combinatorial therapies [2-4]
and multi-target drugs [5] may greatly help us to break or
re-direct the robust behavior of the cell. For the
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Overview and possible extensions of therapy, disease, drug and drug-
target networks. The ovals represent data types (datasets) that have
already been used for network construction (connected with white
arrows) or that could be used to construct similar networks in the
future (connected with black arrows). Datasets are positioned from
top to bottom in the approximate order of their decreasing
complexity; datasets in the same row overlap each other. Numbers
indicate: (1) the drug-therapy network of Nacher and Schwartz [8];
(2) drug-target networks [1,6,7,9]; (3) a disease-gene network [15].
Drug 1
‘Disease gene’ Drug target
Patient Symptom
Possible network representations
Complexity
2
3
Disease Therapyknowledge-based design of appropriate drug combinations
and multi-target drugs, however, we need novel approaches
and techniques to explore the dynamic complexity of
cellular networks after multiple perturbations [24,25].
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During the processing of this manuscript Campillos et al.
[30] published a network of 502 drugs and their side effects
using these data to predict novel drug targets based on the
similarity of side-effect of two chemically dissimilar drugs.
From the same data a side-effect network could also be
constructed, where two side effects are linked, if a drug
exists, which has both. This side-effect network in
combination with the link-prediction methods outlined
above [13,17,18] opens the possibility to predict additional
side effects of existing drugs and drug candidates. Network-
based side-effect prediction would greatly help the
development of better clinical trial protocols, and would
uncover additional possible dangers before the large-scale
use of novel drugs.
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